A detailed history of Royal Bank Of Canada transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 8,275 shares of STRO stock, worth $15,308. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,275
Previous 7,699 7.48%
Holding current value
$15,308
Previous $22,000 27.27%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.88 - $5.01 $1,658 - $2,885
576 Added 7.48%
8,275 $28,000
Q2 2024

Aug 14, 2024

BUY
$2.92 - $5.33 $18,331 - $33,461
6,278 Added 441.8%
7,699 $22,000
Q1 2024

Nov 05, 2024

SELL
$3.27 - $5.65 $20,529 - $35,470
-6,278 Reduced 81.54%
1,421 $8,000
Q1 2024

May 15, 2024

SELL
$3.27 - $5.65 $56,924 - $98,355
-17,408 Reduced 92.45%
1,421 $8,000
Q4 2023

Feb 14, 2024

BUY
$2.07 - $4.54 $18,029 - $39,543
8,710 Added 86.08%
18,829 $80,000
Q3 2023

Nov 14, 2023

BUY
$3.29 - $4.9 $12,646 - $18,835
3,844 Added 61.26%
10,119 $35,000
Q2 2023

Aug 14, 2023

BUY
$4.25 - $5.88 $9,728 - $13,459
2,289 Added 57.43%
6,275 $29,000
Q1 2023

May 15, 2023

SELL
$4.48 - $8.45 $15,523 - $29,279
-3,465 Reduced 46.5%
3,986 $18,000
Q4 2022

Feb 14, 2023

BUY
$5.41 - $8.08 $37,085 - $55,388
6,855 Added 1150.17%
7,451 $60,000
Q3 2022

Nov 14, 2022

BUY
$5.17 - $7.11 $1,804 - $2,481
349 Added 141.3%
596 $3,000
Q2 2022

Aug 15, 2022

SELL
$3.41 - $8.95 $9,841 - $25,829
-2,886 Reduced 92.12%
247 $1,000
Q1 2022

May 16, 2022

SELL
$7.78 - $15.31 $45,022 - $88,598
-5,787 Reduced 64.88%
3,133 $26,000
Q4 2021

Feb 14, 2022

BUY
$14.25 - $23.53 $108,171 - $178,616
7,591 Added 571.18%
8,920 $132,000
Q3 2021

Nov 15, 2021

BUY
$16.88 - $22.38 $15,107 - $20,030
895 Added 206.22%
1,329 $25,000
Q2 2021

Aug 16, 2021

BUY
$18.03 - $23.82 $7,825 - $10,337
434 New
434 $8,000

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $96.5M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.